OPKO Health, Inc.
OPKO Health, Inc. (Nasdaq: OPK) is a diversified healthcare company with pharmaceutical and diagnostic businesses. Its pharmaceutical portfolio includes Rayaldee, an oral treatment for secondary hyperparathyroidism in adults with chronic kidney disease, and NGENLA, a once-weekly growth hormone marketed globally by… From the company’s description.
Over the twelve months to Sep 30, 2026, OPKO Health, Inc. reported revenue of $354.91M, down 44.7% from a year earlier, and a net loss of $148.06M. Its operating margin was −33.7%, and operations used $125.05M in cash. In fiscal 2025, it reported revenue of $606.88M, down 14.9% from fiscal 2024, and a net loss of $225.68M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OPKO Health, Inc. does
In the company’s own words
OPKO Health, Inc. (Nasdaq: OPK) is a diversified healthcare company with pharmaceutical and diagnostic businesses. Its pharmaceutical portfolio includes Rayaldee, an oral treatment for secondary hyperparathyroidism in adults with chronic kidney disease, and NGENLA, a once-weekly growth hormone marketed globally by Pfizer; OPKO receives a share of profits under its partnership. Its subsidiary ModeX develops multispecific immune therapies and vaccines for cancer and infectious diseases, while OPKO’s other development programs include peptide therapies for metabolic and rare disorders. The company also manufactures and distributes pharmaceutical products internationally, and its Irish subsidiary EirGen develops and supplies high-potency oral medicines to customers in more than 60 countries. OPKO reports two segments: pharmaceuticals and diagnostics. The diagnostics segment is primarily BioReference, which provides clinical and specialty laboratory testing to healthcare providers and other customers, including its national 4Kscore prostate cancer testing service. Following asset sales, BioReference focuses on clinical testing in New York and New Jersey, urology, and correctional healthcare; it had approximately 1,373 full-time employees at December 31, 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MIAMI, FL
- Fiscal year end
- December
- CIK
- 944809
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OPKO Health, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OPKO Health, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
OPKO Health, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of OPKO Health, Inc.’s debt, $1.65M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.04%, maturing 2029 to 2029.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OPKO Health, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OPKO Health, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OPKO Health, Inc.'s last four quarterly filings that the numbers alone won't show?”